- Info
- Portfolio
- Significant Ownership
- Insider Ownership
Significant Ownership of Lynx1 Capital Management LP
- Signature - Title
- /s/ Weston Nichols - By: Lynx1 Capital Management GP LLC, General Partner, By: Weston Nichols, Sole Member
- Location
- Dorado
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by Lynx1 Capital Management LP.
Follow Filing Activity
Follow Lynx1 Capital Management LP and return when a new Schedule 13D/G filing appears.
This tracks SEC filing changes for this page using existing product update flows.
Continue schedule research
Related filing hubs for this reporting manager, useful for reinforcing crawl paths across the schedule cluster.
Significant Ownership of Lynx1 Capital Management LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| PASG | Passage BIO, Inc. | Common Stock, par value $0.0001 per share | 20% | $243,245 | -$3,366,967 | 623,704 | -93% | LYNX1 CAPITAL MANAGEMENT LP | 30 Sep 2025 |
| GHRS | GH Research PLC | Ordinary Shares, nominal value $0.025 per share | 17% | $164,840,148 | +$28,597,314 | 10,406,575 | +21% | Lynx1 Capital Management LP | 31 Dec 2025 |
| NEUP | Neuphoria Therapeutics Inc. | Common Stock, par value $0.00001 per share | 16% | $3,877,703 | 875,328 | 0% | Lynx1 Capital Management LP | 26 Dec 2025 | |
| TCRX | TScan Therapeutics, Inc. | Voting Common Stock, par value $0.0001 per share | 15% | $11,393,153 | +$3,625,000 | 7,857,347 | +47% | Lynx1 Capital Management LP | 30 Jun 2025 |
| CGEM | Cullinan Therapeutics, Inc. | Common Stock, par value $0.0001 per share | 14% | $50,697,778 | +$24,599,905 | 8,549,084 | +94% | Lynx1 Capital Management LP | 08 Oct 2025 |
| KRRO | Korro Bio, Inc. | Common Stock, par value $0.001 per share | 11% | $18,351,871 | +$9,599,630 | 1,538,296 | +110% | Lynx1 Capital Management LP | 31 Mar 2026 |
| CCCC | C4 Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 7.3% | $13,557,434 | 7,098,133 | Lynx1 Capital Management LP | 31 Dec 2025 | ||
| ALLO | Allogene Therapeutics, Inc. | Common Stock, par value $0.001 per share | 5.2% | $16,747,073 | 10,874,723 | Lynx1 Capital Management LP | 31 Dec 2024 | ||
| DTIL | PRECISION BIOSCIENCES INC | Common Stock, par value $0.000005 per share | 4.1% | $4,084,982 | -$200,087 | 993,913 | -4.7% | Lynx1 Capital Management LP | 31 Dec 2025 |
| IBIO | iBio, Inc. | Common Stock, $0.001 par value per share | 0% | $0 | 0 | Lynx1 Capital Management LP | 31 Dec 2025 |
Schedules 13D/G Reported by Lynx1 Capital Management LP:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.